Excelra, a global data science and data analytics company, has collaborated with Standigm Inc, a company using artificial intelligence technology for drug discovery and development, it was reported on Tuesday.
According to the contract, Excelra is to offer its small molecule medicinal chemistry intelligence platform GOSTAR to Standigm Inc. GOSTAR provides data including more than eight million compounds, manually designed from three million patents and 200,000 journal articles.
The database includes more than 28 million SAR associated data points. It can be used for various applications across different stages of the drug discovery and development lifecycle and aids in target validation, hit Identification, early lead identification and optimisation.
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results